Boehringer Returns to Sino Biopharma in $7.4 Billion Cancer Pact
Boehringer Ingelheim has struck a new oncology partnership with Sino Biopharma, reviving a relationship that now carries a headline value of up to $7.4 billion. The deal centers on preclinical bispecific T-cell engagers and antibody-drug conjugates, underscoring how large drugmakers are still willing to pay for early-stage cancer assets with long-dated optionality. The agreement adds another major cross-border licensing transaction to a market already defined by capital discipline, pipeline replenishment and intense competition for differentiated oncology platforms. For investors, the structure signals both the scale of demand for next-generation cancer modalities and the long development runway that will determine how much of the deal value ultimately becomes payable.